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Cyclodextrin-based facial amphiphiles: assessing
the impact of the hydrophilic–lipophilic balance in
the self-assembly, DNA complexation and gene
delivery capabilitiesQ1 †
IrisQ2 Pﬂueger,a Coralie Charrat,b Carmen Ortiz Mellet,c José M. García Fernández,a
Christophe Di Giorgio*b and Juan M. Benito*a
Exhaustive structure–eﬃcacy relationship studies on nonviral gene delivery systems are often hampered
by the ill-deﬁned or polydisperse nature of the formulations. Facial amphiphiles based on rigid cage-type
molecular scaﬀolds oﬀer unique possibilities towards these studies. Taking advantage of regioselective
functionalization schemes, we have synthesized a library of cationic cyclodextrin (CD) derivatives combin-
ing a range of hydrophilic and lipophilic domains. We have scrutinized how the hydrophilic–lipophilic
balance (HLB) around the CD scaﬀold determines their self-assembly capabilities and the DNA binding
and release abilities of the corresponding CD : DNA nanocomplexes (CDplexes). These features have been
ultimately correlated with their capabilities to deliver a reporter luciferase-encoding pDNA into COS-7
cells. The ensemble of results demonstrates that ﬁne tuning of the HLB is critical to induce compaction of
DNA by the CD-based facial amphiphiles into transfection-productive CDplexes.
Introduction
In vivo gene therapy has emerged as a fascinating therapeutic
paradigm. The possibility to interfere with virtually any cellular
metabolic process by specifically up- or down-regulating
protein expression with exogenous nucleic acids holds poten-
tial prospectsQ4 for the treatment of both, inherited or acquired
diseases. Notwithstanding, its clinical impact is yet scarce as a
consequence of the poor bioavailability of gene material and
the biological hurdles impairing their eﬃcient delivery to the
therapeutic targets.1–3 Nucleic acids are highly negatively
charged molecules with low membrane permeability and
metabolical stability. Their therapeutic use requires the devel-
opment of purpose-conceived delivery systems, which remains
so far a largely unmet challenge.4 Transfection is a multistep
process, involving among others nucleic acid condensation
and protection from extra and intracellular media, cellular
uptake, endosome escape, organelle targeting and cargo
release; ineﬃciencies at any stage result in a dramatic decrease
in its pretended eﬀect Q5.5–7 Research eﬀorts on nonviral gene
vectors have intensified in the last two decades, seeking at
improving the loading capacity, safety, and functional tunabil-
ity to overcome the various biological barriers.3,8–11 The ability
to form stable nanocomplexes under physiological conditions,
providing protection of the gene material from the action of
nucleases, is a key aspect that has to be taken into consider-
ation when designing an eﬃcient gene carrier.12,13 Yet, this
self-assembly process must be reversible, since upon arrival
into the intracellular medium the nucleic acid must be
released; it becomes a liability for carriers to bind their cargo
too tight, as overbinding impairs access to the translational
machinery. Indeed, releasing ineﬃciencies are among the
greatest obstacles for non-viral gene delivery14,15 and there is a
clear consensus that a balance between protection and DNA
release should be sought.5,16,17 Tackling this key challenge has
brought into focus the analysis of series of polymeric carriers
to probe the influence of factors such as polymer size,15,18 cat-
ionic density,19 conformation,20 hydrophilic–lipophilic
balance (HLB),21 or simultaneously several of them.22,23
Vector performance optimisation strategies will greatly
benefit from accurate structure–activity relationship studies
and chemical tailoring-compatible approaches.24 However, the
polydisperse or multicomponent nature of most formulations
severely restrict these initiatives.25 Alternatively, molecularly
†Electronic supplementary information (ESI) available: Experimental details for
nanoparticle formulation, biophysical characterization and biological evalu-
ation, and copies of the NMR (1H and 13C) and ESI-MS spectra for all new com-
pounds. See DOI: 10.1039/c6ob01882c
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well-defined entities endowed with facial amphiphilicity based
on rigid cage-type scaﬀolds,26 such as fullerenes,27 calixar-
enes,28,29 pillarenes,30 cyclopeptides,31 or cyclooligosachar-
ides,32 oﬀer unprecedented opportunities in this regard.
Among them, cationic cyclodextrin (CD)-based molecular gene
vectors have gained a prominent position. CDs display a large
number of hydroxyl groups with a well-defined spatial orien-
tation that can be derivatized by synthetic means with relative
ease. This feature oﬀers virtually unlimited possibilities for
functional tailoring of the CD core, which, together with their
inherent biocompatibility and commercial availability, prob-
ably accounts for their profuse exploitation in the field.32
Polycationic amphiphilic CDs (paCDs) readily promote nucleic
acid condensation into stable nanometric particles (CDplexes)
that mediate relevant expression levels of reporter and thera-
peutic genes in a variety of cell lines both in vitro33,34 and
in vivo.35,36 CDplex formation is presumed to proceed through
a two-step process involving (i) electrostatic-driven complexa-
tion of the DNA template of individual paCD entities along the
polyphosphate chain; and (ii) hydrophobic-driven dehydration
and compaction into nanocomplexes in which quasi-parallel
nucleic acid segments are bridged by paCD bilayers (Fig. 1). It
has been proposed that the balance between the cationic
charge density in the hydrophilic rim and the hydrophobicity
of the opposite face in the paCD structure governs this hier-
archical assembly process, probably by controlling the revers-
ible formation of the multilayer assembly.37 Even though the
notion of the HLB remains qualitative, studies on the lipophili-
zation of pre-existing cationic carriers have revealed relevant
performance improvements.38 Interestingly, recent results39
have shown that nanocomplexation of nucleic acids by non-
amphiphilic cationic CDs can be elicited by promoting their
supramolecular arrangement into dimeric species emulating
the basic components of lipid-like bilayers.
In this contribution we aim at providing a deeper insight
into the molecular basis underlining the eﬃcacy of facial
amphiphiles as gene vectors by pinpointing how HLB controls
hierarchical paCD self-assembly around DNA strands and the
stability of the corresponding CDplexes. First, a library of βCD
derivatives combining an array of cationic and lipophilic
elements in segregated domains was built (Chart 1). Next, the
kinetics and dynamics of the paCD : DNA interactions involved
in CDplex formation and dissociation in aqueous media were
scrutinized for each library member individually. Finally, the
pDNA-transfecting capabilities in cellulo have been assessed
and critically correlated with the molecular and supramolecu-
lar features. Collectively the data point out that, despite all cat-
ionic CDs eﬃciently complexing DNA, gene transfer capabili-
ties critically depend on a delicate balance between the factors
influencing reversible CDplex assembly–disassembly among
which the HLB plays a central role.
Results and discussion
Library design and synthesis
For the goals of this work, we have taken advantage of a pre-
viously described strategy for face-selective functionalization of
native CDs permitting the construction of precise functional
group displays.33,40 The strategy consists of the regioselective
cysteaminylation of the primary hydroxyl rim, followed by
exhaustive acylation of the secondary ones (Scheme 1). The
hydrophilic (cationic) domain can be further tailored by using
a click-type thiourea-forming reaction.41 For each multihead
cationic cluster architecture, the length of the hydrophobic
tails at the opposite face can be varied preserving full homo-
geneity and a C7-symmetrical arrangement by DMAP-promoted
acylation with diﬀerent acyl anhydrides, overall keeping a
limited synthetic cost. Two series of cationic CDs featuring
7 or 21 potentially cationizable amino groups on the primary
CD rim, respectively (Chart 1, 7- and 21-series in the left and
right panels) were thus prepared. The members of each series
are furnished at their secondary rim with 14 acyl groups of
varied length (from acetyl to hexanoyl). Each series was com-
pleted with the corresponding non-amphiphilic CD derivative
keeping the secondary hydroxyls unmodified (7H and 21H). In
brief, synthesis started from the common precursor per-(C-6)-
bromo βCD,42 which was transformed into the cysteaminylated
derivative 1 33 upon treatment with Boc-protected 2-aminoetha-
nethiol. Compound 1 was then subjected to acylation of the
Fig. 1 Schematic representation of the stepwise process leading to
CDplex formation, consisting on (i) the initial electrostatic interaction of
paCDs with the negatively-charged nucleic acid, and (ii) the latter hydro-
phobic compaction forming a bilayered paCD shell around the nucleic
acid template.
Chart 1 Structure of 7- and 21-cationic CD series with indication of
their structure-correlated notation (7 or 21 refer to the number of
potentially protonatable amines at the primary rim of the CD scaﬀold,
while subscripts indicate the functionalization at the secondary rim).
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secondary hydroxyls to eﬃciently yield derivatives 2–5 in
73–80% yield (Scheme 1). TFA-promoted Boc cleavage, fol-
lowed by multi-thiourea coupling of the resulting heptaamines
6 and 8–10 with 2-(tert-butoxycarbonylamino)ethyl isothio-
cyanate,43 aﬀorded the Boc-protected adducts 11–14 (7-series)
in 75–94% overall yield after column chromatography purifi-
cation. Alternatively, coupling the cysteaminyl derivatives 6–10
to 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethyl iso-
thiocyanate33 eﬃciently furnished the Boc-protected dendritic
derivatives 15–18 (21-series) in 62–95% overall yield
(Scheme 1). The non-amphiphilic derivatives 19 and 20 were
prepared from the corresponding acetylated adducts (11 and
15, respectively) by Zemplén transesterification in methanolic
NaOMe (Scheme 1).
Treatment of the Boc-protected thiourea adducts with con-
centrated TFA (either in water or DCM) has been shown to
quantitatively produce the corresponding cationic amphi-
philes.33,44 However, this protocol concomitantly produced
extensive ester hydrolysis in substrates with the shorter acyl
chains (acetyl and propanoyl, see ESI, Fig. S29†). The use of
anhydrous TFA at 0 °C and short reaction times, followed by
freeze-drying from aqueous HCl prevented this undesired side-
reaction and furnished the target paCDs quantitatively as their
hydrochloride salts (Scheme 1 and Chart 1). The purity and
homogeneity of each library member was assessed by NMR,
ESI-MS, and combustion analysis.
The optimal conditions to obtain a satisfactory 1H NMR
spectral resolution for each paCD derivative varied from case
to case (see Experimental section) and were very much depen-
dent on the solvent, pH and acquisition temperature. This
probably reflects the disparate self-assembling capabilities of
these facial amphiphiles as a function of their molecular struc-
ture. For instance, the very broad resonance signals exhibited
by derivative 7Pr in D2O-containing solution dramatically
resolved in DMSO-d6 (Fig. S30†), indicating the aggregating
tendency in aqueous media. On the other hand, derivative 7Hex
exhibited a complex spectrum at acidic pH that readily simpli-
fied upon neutralization (Fig. S31†), which was attributed to
slow proton exchange between cationic head groups in an
acidic environment even at relatively high temperatures
(50 °C). As expected, non-amphiphilic CDs 7H and 21H did not
exhibit this behavior.
DNA complexing abilities of cationic CDs
Study of CDplex formation by DLS. To analyze the influence
of the HLB on nucleic acid complexing capabilities, the size
and ζ-potential of paCD : DNA CDplexes were measured by
dynamic light scattering (DLS), respectively. Due to the limited
availability of the transfection plasmid, preliminary assess-
ments were made at several N/P ratios using a commercial calf
thymus DNA (ctDNA) as pDNA surrogate. None of the cationic
CDs formed ordered aggregates in the absence of DNA when
dispersed either in water or HEPES buﬀer. Rather polydisperse
and unstable aggregate populations were obtained in most
cases. In contrast, in the presence of ctDNA all candidates ren-
dered rather homogenous nanocomplexes (60–90 nm, Fig. 2)
at ionizable nitrogen/phosphate (N/P) ratios of 5 and 10, thus
confirming the templating role of DNA in CDplex assembling
(see Fig. S34†). Minor size and ζ-potential variations were
observed between the two N/P ratios considered, suggesting
that once DNA is fully complexed the excess of cationic CD
plays a minor role in CDplex morphology. Particle size distri-
bution analysis in the N/P 5–10 window indicates that single
population of CDplexes are formed from most formulations,
with narrow size distributions especially in the case of paCD
derivatives equipped with the longer acyl chains (e.g.
Fig. S34C†). CDplexes formulated at N/P ≤ 2 averaged larger
Scheme 1 Synthesis of paCDs in the 7- and 21-series. For a more intui-
tive structural correlation, notations combine the number of protonable
amine groups (7 or 21) with an acronym of the acyl groups at the
secondary rim.
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particle sizes and polydispersities than the corresponding for-
mulations at N/P 5 or 10 (data not shown), indicating sub-
optimal particle compaction and, probably, reduced stability.
Transmission electron microscopy (TEM) and gel electrophor-
esis retardation experiments (vide infra) also support this
hypothesis.
ζ-Potential values showed higher variability within each
paCD series. Thus, the most hydrophilic derivatives (7H, 7Ac,
7Pr and 21H, 21Ac, 21Pr) featured mildly positive potentials in
the 31.6–37.3 mV range, regardless of the N/P (5 or 10) or the
nature of the cationic heads, whereas the most lipophilic CDs
(7But, 7Hex and 21But, 21Hex) exhibited significantly higher
ζ-potentials, in the 49–85 mV range.
Agarose gel electrophoresis retardation experiments. The
above results were contrasted with agarose gel electrophoresis
shift assays. CD : ctDNA complexes were formulated at
diﬀerent N/P ratios (0.5 to 20) and their electrophoretic mobi-
lity was compared to that of ctDNA alone. The accessibility of
the nucleic acid material in the nanocomplexes was examined
by staining with the intercalating agent GelRed™. As expected,
all cationic CDs inhibit ctDNA migration, but remarkable
diﬀerences in both the capacity to neutralize DNA and to
protect it from GelRed™ intercalation as a function of the HLB
is observed. The non-amphiphilic cationic CDs 7H and 21H are
the most eﬃcient at neutralizing ctDNA, although incomplete
DNA protection from the media is observed even at the highest
N/P ratio tested (Fig. 3, first row). Conversely, DNA retardation
and protection against the intercalating agent gradually
increased in parallel to the N/P ratio in the case of DNA : paCD
formulations, the facial amphiphiles equipped with the
longest hexanoyl chains 7Hex and 21Hex being the most
eﬃcient at both tasks. At a first glance, derivatives from the
7-series seems to be superior to their 21-series counterparts,
which might be rationalized considering that a 3-fold higher
molar concentration is required for the former to achieve iden-
tical N/P ratios. Except for 7But and 7Hex, N/P values >2 are
required to achieve complete DNA protection. Qualitatively
similar results were obtained when replacing ctDNA by pDNA
(data not shown).
Transmission electron microscopy of CDplexes. The TEM
micrographs of N/P 10 pDNA : paCD formulations evidenced
significant diﬀerences on the self-assembly properties of the
facial amphiphiles as a function of the HLB as well as on their
ability to form mixed nanocomplexes where the condensed
plasmid is isolated from the environment. The paCDs
equipped with the shorter acetyl or propionyl chains (e.g. 7Ac
and 21Pr, Fig. 4A and B) tend to self-assemble into small
nanoaggregates (10–20 nm diameter), previously unnoticed in
DLS measurements. These particles are likely to interact
electrostatically with pDNA molecules to form, initially, large
(>200 nm) multiparticle : plasmid aggregates, as observed in
Fig. 4A. Eventually, these aggregates can further collapse to
aﬀord multilamellar CDplexes, probably unimolecular in
Fig. 2 Hydrodynamic diameter (bars, left axis) and ζ potential (circles,
right axis) of CDplexes formulated at N/P 5 (empty bars and circles) and
10 (ﬁlled bars and circles).
Fig. 3 ctDNA retardation and protection capacity of CDs (7-cationic
CDs, left column; 21-cationic CDs, right column) in agarose gel at
diﬀerent N/P ratios (0.5, 1, 2, 5, 10 and 20). Environmentally accessible
nucleic acid is visualized by GelRed™ staining.
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pDNA, in which paCD bilayers alternate with DNA segments.
CDplexes and paCD vesicles coexist in these formulations and
can be observed simultaneously in the TEM images. In sharp
contrast, in the formulations prepared from butyroyl and hexa-
noyl paCD derivatives (e.g. 7But and 21Hex, respectively) only
the collapsed well-defined CDplexes are observable, suggesting
that the paCD in excess does not form stable self-assembled
constructs (Fig. 4C and D). In summation, the ensemble of
TEM data strongly suggests that in the first scenario the
dynamic equilibrium underlining CDplex assembly–disassem-
bly involves vesicular species, whereas in the second case it
implies molecular entities. Shifting from one situation to the
other drastically depends on the HLB, the transition occurring
between paCDs bearing propanoyl and butanoyl chains at the
secondary hydroxyls in the two series of facial amphiphiles
here studied. The results evidence that, as far as concerning
self-assembling abilities, the volume of the lipophilic cluster
(determined by acyl chain length) is the decisive factor, as
compared to the cationic density. It is reasonable to argue that
breaking the paCD vesicles implies a certain energy penalty
that renders CDplexes from acetylated and propanoylated
paCDs less stable than the butanoylated and hexanoylated
homologues, in agreement with the agarose gel retardation
experiments above discussed.
DNA releasing abilities of CDplexes
Heparin competition experiments. A functional gene vector
must not only condense and protect the gene material by
forming nanocomplexes capable of crossing biological mem-
branes, but also must deliver the nucleic acid cargo at the
right spot. The steps leading to CDplex disassembly and DNA
release are at least as important as those involved in DNA pro-
tection to the overall transfection process. Previous results
indicated that facial amphiphilicity furnishes CDplexes with
higher tolerance to saline stress33 as compared to non-amphi-
philic CD polycations, which readily dissociate at high ionic
strength.45 This is reasonable considering that the formation
of the latter exclusively rely on electrostatic interactions,
whereas in the case of paCDs a hydrophobic contribution is
summed up. To compare the relative stability of CDplexes
derived from the diﬀerent CDs in this study in a biological
medium, competitive displacement assays were performed
using the polyanionic polysaccharide heparin46,47 as displa-
cing competitor and a fixed incubation time (10 min). The
process was indirectly followed by monitoring the fluorescence
intensity of a DNA intercalating agent.31 CDplexes were formu-
lated at N/P 5, thus ensuring complete DNA protection and a
weak residual fluorescence background. Incubation of the
CDplexes in the presence of increasing concentrations of
heparin displayed very dissimilar profiles (Fig. 5). CDplexes
formulated with 7But and 7Hex were rather invulnerable to
heparin-induced disassembling up to the maximum concen-
tration tested (2 mg mL−1). The stability slightly decreased for
CDplexes formulated with 7Pr and was very limited for 7Ac, for
which the maximum fluorescence intensity, meaning total
DNA release, is recovered with less than 50 μg mL−1 of
heparin. The observed CDplex stability trend is inversed as
compared with the tendency of the paCD to form 10–20 nm
nanoaggregates as inferred from the TEM analysis. The results
support the hypothesis that the capacity of facial amphiphiles
to complex and release DNA is closely related to the balance
between their tendency to form single-component self-
assembled constructs versus their propensity to undergo DNA-
Fig. 4 TEM micrographs of CDplexes formulated at N/P 10 with (A) 7Ac,
(B) 21Pr, 7But (C) and (D) 21Hex in the presence of pDNA. The symbols ●,
◆, and # indicate small (10–20 nm) CD vesicles, multivesicle : DNA
aggregates, and CDplexes, respectively.
Fig. 5 Concentration-dependent heparin-induced CDplex dissociation:
RedSafe™ ﬂuorescence recovery upon incubation of CDplexes formu-
lated at N/P 5 with ctDNA and 7-cationic centre CDs 7H (■), 7Ac (▲),
7Pr (●), 7But (◆), and 7Hex ( ) with diﬀerent amounts of heparin for
10 min. The ﬂuorescence increase is due to the intercalation of the
probe into ctDNA released from dissociated CDplexes.
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templated alignment into multilayered architectures, which
can be finely tuned by adjusting the HLB.
It is interesting to note that CDplexes formulated with the
non-amphiphilic CD 7H resisted better than the acetylated ana-
logue 7Ac against heparin-promoted dissociation; maximum
fluorescence could only be recovered at concentrations
>1 mg mL−1. In this case the mechanism depicted in Fig. 1 is
not operative and a diﬀerent supramolecular organization
must take place. Results obtained with the 21-cationic centre
paCD series were qualitatively similar.
CDplex dissociation dynamics. The above competition assay
provides a “steady-state” vision of CDplex stability and propen-
sity to release the DNA cargo. Yet, assessing the dynamics of
the disassembly process is additionally necessary to properly
interpret the eﬀect of structural features of the vector in DNA
delivery capabilities. Towards this end, CDplex stability was
next probed in a similar experimental setup over time at a
fixed heparin ratio (0.8 mg mL−1). As illustrated in Fig. 6 for
the CDplexes formulated with CDs of the 21-series, dis-
sociation kinetics are drastically influenced by acyl chain
length, paralleling concentration-dependent experiments: fluo-
rescence recovery, therefore DNA release, is much faster for
CDs endowed with the shorter acetyl or propyl chains as com-
pared with the butanoylated or hexanoylated derivatives
(Fig. 6).
For comparative purposes, the same experiment was run on
polyplexes formulated with bPEI (25 kDa) at the optimal trans-
fection conditions (i.e. N/P 10). The experiment indicated a
dissociation rate intermediate between that of 21Pr and 21But
or 21Hex CDplexes (Fig. S35†). The non-amphiphilic derivative
21H (blue line, Fig. 6) again challenged the tendency of its
amphiphilic counterparts. The dissociation of these CDplexes
seems to be retarded at the beginning and slowly begins after
ca. 200 min, which resembles the tendency displayed by bPEI
polyplexes (see Fig. S35†) and might be illustrative of the
purely electrostatic interactions involved in these systems.
Nevertheless, stability of 21H CDplexes is far lower than that of
bPEI polyplexes. The qualitative reliability of the experimental
setup was confirmed at larger and shorter heparin concen-
trations that aﬀorded the expected fluorescence recovery rate
increase and decrease, respectively (data not shown).
Cell transfection capabilities of CDplexes
Gene carrier capabilities were assessed on African green
monkey fibroblast-like COS-7 cells using a luciferase-encoding
gene (pTG11236, pCMV-SV40-luciferase-SV40pA). Naked pDNA
and JetPEI polyplexes were used as negative and positive con-
trols, respectively. The assays were run with CDplexes formu-
lated at N/P 2, 5 and 10 in 10% serum-containing medium.
The level of exogenous luciferase expression (relative to the
total amount of proteins) and the cell viability (relative to
untreated controls) were measured for each CDplex formu-
lation (Fig. 7; data at N/P 10 omitted for clarity; the full data
set is collected in ESI, Fig. S36†).
The non-amphiphilic CDs 7H and 21H featured negligible
gene transfer abilities under these experimental conditions,
Fig. 6 Time-dependent heparin-induced CDplex dissociation.
RedSafe™ ﬂuorescence recovery upon incubation of CDplexes formu-
lated at N/P 5 with ctDNA and 21-cationic CDs 21H (blue), 21Ac (black),
21Pr (orange), 21But (green), and 21Hex (red) with heparin (800 μg mL−1).
Fluorescence increase is due to the intercalation of the probe into
ctDNA released from dissociated CDplexes. Relative ﬂuorescence levels
correspond to solutions of the ﬂuorescent probe in the absence (0%)
and in the presence of ctDNA (100%). Note that initial measurement
does not correspond necessarily with t = 0 minutes, since a few minutes
(ca. 10 min) are required to set up the whole experiment.
Fig. 7 In vitro transfection eﬃciency (panel A) and cell viability (panel
B) in COS-7 cells in 10% serum-containing medium of CDplexes formu-
lated with the luciferase encoding plasmid pTG11236 at N/P 2 (empty
bars and triangles) and 5 (ﬁlled bars and circles). Naked pDNA and
JetPEI polyplexes (N/P 10) were used as negative and positive controls,
respectively. Experiments were run by triplicate.
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regardless the N/P ratio (Fig. 7A), which might be explained on
the basis of their modest DNA compacting capabilities in the
light of the above experimental evidence. Only a modest luci-
ferase expression increase is noticed at N/P 10 for the hepta-
cationic 7H derivative, but with an intolerable toxicity
(Fig. S36†). Virtually the same results were observed for
CDplexes formulated with the paCDs featuring the shorter acyl
chains (acetyl and propanoyls), regardless of the cationic
density or N/P ratio. Similarly to their non-amphiphilic
counterparts, toxicity is not an issue at low N/P ratios (2 and 5)
but seriously increases at N/P 10, especially for the heptacatio-
nic derivatives (Fig. S36†). The ineﬃciency of these CDplexes
to fulfil their task correlates with their relatively low stability,
which probably leads to premature pDNA release.
CDplexes formulated with butanoylated and hexanoylated
paCDs gradually increased their transfection eﬃciency with
N/P ratio. At identical N/P ratio, the eﬃciency of derivatives
with 7 cationic centres largely exceeded that of their
21-cationic analogues. Nevertheless, it must be recalled that
N/P normalization implies a 3-fold higher molar proportion
for the former. At N/P 5, paCDs 7But and 7Hex were revealed as
the best carriers, only 10- and 30-fold less eﬃcient than the
gold standard JetPEI at its optimal N/P 10 ratio (Fig. 7A), and
with a far milder cytotoxic profile (Fig. 7B). Indeed, eﬃciency
could be further enhanced at N/P 10 for 7But up to parallel
JetPEI performance, but at the cost of a significant drop in cell
viability (Fig. S36†).
Fluorescence-assisted cell sorting (FACS) experiments using
a fluorescently labelled plasmid (see ESI for experimental
details, Fig. S37†) indicated that CDplex uptake is rather fast,
since even the less stable CDplexes are detected inside COS-7
cells to a relevant extent after the incubation time (24 h). The
question of whether further intracellular traﬃcking and fate is
conditioned by ineﬃcient endosomal release has been also
addressed by performing transfection assays in the presence of
the endosomolytic agent chloroquine. Luciferase expression
promoted by 7But and 7Hex at N/P 5 was not aﬀected in the
presence of chloroquine and only a modest increase was
detected for 21But and 21Hex, indicating that endosome escape
is not a bottleneck for transfection in these cases (Fig. S38†).
The eﬃciency of the rest of formulations (already very poor)
featured negligible variations. It can be speculated that
eﬃcient transfection requires the CDplexes to be suﬃciently
stable to remain assembled, providing full protection to the
DNA cargo, in the early endosome at the vicinity of the cell
membrane and undergo escape and DNA release upon acidifi-
cation in the late endosome, near the nucleus, before lysosome
fusion. Indeed, pDNA diﬀusion in the cytoplasm will be too
slow to allow the nucleus to be reached before digestion by cyto-
plasmic nucleases.48 CDplexes formulated with paCDs
equipped with butanoyl and hexanoyl chains are not only more
stable than CDplexes formulated with shorter-acyl-chain paCDs,
but also exhibited significantly larger pH buﬀering capabilities
(Table S1 and Fig. S32, S33†), probably benefitting from a
proton sponge-type behaviour similar to that postulated for PEI-
based carriers,49 which prevents premature disassembly.
Conclusions
Correlation of non-viral gene carrier topology with transfection
eﬃciency is often impaired by the limited control over the
vector structure due to polydispersity or the lack of diversity-
oriented synthetic tools. The body of work here discussed pro-
vides a proof of concept of the potential of strategies based on
monodisperse molecular entities and flexible synthetic strat-
egies, for structure–activity relationship analysis, tailoring of
the self-assembly properties of CD-based vectors and optimiz-
ation of gene delivery eﬃciencies. Variations in nucleic acid
compaction, nanocomplex stability and transfection capabili-
ties within series of homologous βCD-based facial amphi-
philes have been correlated with their HLB. The library
member incorporating a cationic corona with seven 2-amino-
ethylthioureido moieties on the primary rim and a multitail
lipophilic domain of 14 butanoyl chains at the secondary rim,
namely 7But, was found to feature the best suited properties.
The HLB in 7But seems to be optimal to both electrostatically
interact with polyphosphate backbones and promote desolva-
tion and compaction of DNA through hydrophobic inter-
actions, leading to the spontaneous formation of nano-
particles where the gene material is fully protected from the
environment. As described in previous studies on related struc-
tures,50 these nanocomplexes might be stable enough to
remain assembled in the early endosome after cellular uptake,
enabling active traﬃcking in the cytoplasm and release of the
DNA cargo at the nucleus vicinity. The flexibility of the strategy
and its potential to pinpoint minute aspects of the relation-
ship between macromolecular structure and functional capa-
bilities oﬀer new perspectives in the field.
Experimental
General methods
Reagents and solvents were purchased from commercial
sources and used without further purification. NMR spectra
were recorded at 500 MHz. 2D COSY, HSQC, and 1D TOCSY
experiments were used to assist NMR assignments.
Electrospray mass spectra (ESIMS) were obtained with a Bruker
Esquire6000 instrument. Compounds 1, 2, 5, 6, 10, 11, 14, 15,
18, 7H, 7Hex, 21H, and 21Hex were synthesized as previously
reported.33,44
Preparation of CD : DNA CDplexes
Two diﬀerent nucleic acids were used: DNA sodium salt from
calf thymus (ctDNA) and the luciferase-encoding plasmid
pTG11236 (pCMVSV40-luciferase-SV40pA),51 a 5739 bp
plasmid. Due to the scarce pDNA sample availability, ctDNA
was used for most physicochemical characterization studies,
while pDNA was utilized in transfection assays. Eventually,
comparative CDplex formation tests in the presence of both,
ctDNA and pDNA, were carried out to validate ctDNA as pDNA
surrogate. The quantities of compound used were calculated
according to the desired DNA concentration, the N/P ratio, the
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molecular weight and the number of protonatable nitrogen
atoms in the corresponding cationic CD. JetPEI and bPEI
(25 kDa) were used as standard references. In particular, DNA
concentrations applied were 60 μg mL−1 (i.e. 180 µM phos-
phate) for gel electrophoresis, 20 μg mL−1 (i.e. 60 µM phos-
phate) for nanoparticle size, polydispersity index (PDI) and
ζ potential measurements, 100 μg mL−1 (i.e. 303 µM phos-
phate) for transmission electron microscopy, 2 µg mL−1 (i.e.
6 µM phosphate) for fluorimetric DNA : paCD binding studies,
4 µg mL−1 (i.e. 12 µM phosphate) for heparin competitive dis-
placement assays and 5 µg mL−1 (i.e. 15 µM phosphate) for
in vitro transfection experiments.
For the preparation of CDplexes, typically DNA was diluted
in HEPES (20 mM, pH 7.4) to the desired final concentration
as specified above, and then the desired amount of CD deriva-
tive was dispersed in this solution from a stock solution in
DMSO (typically 1–10 mM). The resulting mixture (with a final
DMSO content below 1% in all cases) was instantly vortexed
thoroughly and the complexes were incubated for one hour
prior to subjecting them to characterization or transfection
experiments.
CDplex characterization
Particle size, polydispersity index (PDI) and ζ potential were
determined by dynamic light scattering (DLS) using a Zetasizer
Nano (Malvern) with the following settings: automatic
sampling time; three measurements per sample; medium vis-
cosity, 1.054 cP; refractive index, 1.33; scattering angle, 173°;
λ 633 nm; medium dielectric constant, 80; temperature, 25 °C;
beam mode F(Ka) 1.5 (Smoluchowsky). Data were analyzed
making use of the multimodal number distribution software
included in the instrument. Results are presented as volume
distribution of the major population by the mean diameter
and its standard deviation. Before each series of experiments,
the performance of the instrument was calibrated with either
90 nm monodisperse latex beads for DLS or with DTS 50 stan-
dard solution for ζ potentials. Experiments were run in
triplicate.
Agarose gel electrophoresis shift assays were run in 0.8%
(w/w) agarose gel in TAE buﬀer (1 : 1 : 1 Tris/acetate/EDTA) and
stained with GelRed™ (Biotium). CDplexes were prepared as
above described according to the desired ctDNA concentration
(180 µM phosphate) at N/P ratios ranging from 0.5 to 20. The
samples were prepared by mixing 18 µL of each CDplex formu-
lation and 2 µL of loading buﬀer (5 mL glycerol, 250 µL TAE,
1 mL bromophenol blue and 2.75 mL water). The samples
were submitted to electrophoresis for approximately 20 min at
150 V. DNA was visualized after photographing (λ 302 nm)
using a transilluminator.
Transmission electron microscopy
Formvar-carbon-coated grids previously made hydrophilic by
glow discharge were placed on top of small drops of the
CDplex samples (HEPES 20 mM, pH 7.4, pDNA 303 μM phos-
phate) prepared as described above. After 1–3 min of contact,
grids were negatively stained with a few drops of 1% aqueous
solution of uranyl acetate. The grids were then dried and
observed using a Philips CM12 electron microscope working
under standard conditions. All these experiments were repro-
duced twice on each formulation.
CDplex formation and dissociation dynamics
CDplex formation and dissociation was monitored by fluo-
rescence quenching of an intercalating agent. Experiments
were performed on a Varian Cary Eclipse Fluorescence
Spectrophotometer using ctDNA (2 µg mL−1, 6 µM phosphate).
For CDplex formation studies, a solution of staining agent
RedSafe™ (iNtRON Biotechnology) was prepared. RedSafe™
fluorescence emission was measured at 525 nm (λex 295 nm).
Fluorescence emission of the buﬀer solution was taken as
reference. When ctDNA was added to the RedSafe™ buﬀer
solution (final concentration 3 µM phosphate), the fluo-
rescence reading of the RedSafe™-DNA solution increased
drastically. To this solution, aliquots of stock solutions of the
corresponding paCD derivative in DMSO (50–1000 µM) µL por-
tions were added in order to obtain ascending N/P ratios from
0.1 to 10 approximately. These N/P ratios correspond to CD
concentrations ranging from ca. 0.03 to 8.6 µM. Fluorescence
emission was recorded after each addition following equili-
bration (5 min). As the N/P ratio increases, fluorescence inten-
sity decreases, indicating that DNA condensation and sub-
sequent dye exclusion by CDplex formation is taking place.
Aliquots of the paCD stock solution were added until no
further decrease in fluorescence intensity could be observed.
To assess the relative stability of CDplexes, competitive dis-
placement assays were performed on CDplexes at N/P ratio
5 using heparin. The eﬀect of heparin on the CDplexes dis-
sociation was evaluated by means of the change in relative
fluorescence intensity obtained with the fluorescence probe
RedSafe™. CDplexes were formulated from a 6 µM (phos-
phate) ctDNA solution in HEPES (20 mM, pH 7.4) containing
RedSafe™. Aliquots of 150 µL of these CDplexes were trans-
ferred to the wells of a 96-well plate. Then, diﬀerent volumes
of heparin from stock solutions (100–10 000 µg mL−1 in
HEPES 20 mM, pH 7.4) were added to each well and the final
volume was adjusted to 250 µL (final heparin concentrations
in the range of 5–2000 µg mL−1). The plates were incubated for
10 min at rt prior to time-dependent fluorescence intensity
measurements with a Varian Cary Eclipse Fluorescence
Spectrophotometer equipped with a microplate reader, as indi-
cated above. Naked ctDNA and bPEI were processed in a
similar manner as indicated for the CDplexes and used as
references.
In vitro transfection
Twenty-four hours before transfection, COS-7 cells were grown
at a density of 2 × 104 cells per well in 96-well plates in
Dulbecco modified Eagle culture medium (DMEM; Gibco-BRL)
containing 10% foetal calf serum (FCS; Sigma) in a wet (37 °C)
and 5% CO2/95% air atmosphere. The paCD /pDNA CDplexes
or bPEI/pDNA polyplexes were diluted to 100 μL in DMEM in
order to have 0.5 μg of DNA in the preparation. The culture
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medium was removed and replaced by 100 μL of the complexes
in DMEM. After 4 h and 24 h, 50 and 100 μL of DMEM sup-
plemented with 30% and 10% FCS, respectively, were added.
After 48 h, the transfection was stopped, the culture medium
was discarded, and the cells washed twice with 100 μL of PBS
and lysed with 50 μL of lysis buﬀer (Promega). The lysates were
frozen at −32 °C, before the analysis of luciferase activity. This
measurement was performed in a LB96P luminometer
(Berthold) in dynamic mode, for 10 s on 10 mL on the lysis
mixture and using the “luciferase” determination system
(Promega) in 96-well plates. The total protein concentration
per well was determined by the BCA test (Thermo Scientific™
Pierce™ BCA protein assay kit), according to the supplier spe-
cifications. Luciferase activity was calculated as femtograms
(fg) of luciferase per mg of protein. The percentage of cell via-
bility of the nanocomplexes was calculated as the ratio of the
total protein amount per well of the transfected cells relative to
that measured for untreated cells × 100%.
In vitro transfection in the presence of endosomolytic agent
After twenty-four hours of cell culture, the complex CD deriva-
tive/DNA or PEI/DNA were diluted to 100 μL in DMEM contain-
ing 100 µM chloroquine (Sigma-Aldrich). The culture medium
was removed from the cells and replaced by the solution of
complexes. After 4 h of transfection in the presence of endoso-
molytic agent, the culture medium was aspirated, and the cells
washed with 100 µL of PBS and covered by 150 µL of DMEM
supplemented with 10% FCS. Another 100 µL of 10% FCS
DMEM were added after 24 h of transfection. After 48 h, the
transfection was stopped and the protocol was continued as
described above.
Synthesis
Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-2,3-di-O-
propanoyl]-cyclomaltoheptaose (3). To a solution of 1 33 (1.0 g,
0.44 mmol) in dry DMF (30 mL) under nitrogen atmosphere,
DMAP (2.28 g, 18.7 mmol, 3 eq.) and propanoic anhydride
(3.2 mL, 24.9 mmol, 4 eq.) were added at 0 °C. The reaction
mixture was allowed to warm to rt and stirred overnight. Then,
MeOH (130 mL) was added and the reaction mixture was
further stirred for 1 h. The solvents were removed under
reduced pressure and H2O (60 mL) was added to the reaction
mixture, which was then extracted with DCM (4 × 60 mL). The
organic layer was successively washed with 1 N aq. HCl (2 ×
50 mL) and a saturated aqueous solution of NaHCO3 (50 mL),
dried over Na2SO4, filtered and reduced in vacuum. The crude
product was purified by flash column chromatography (1 : 2 →
1 : 1 EtOAc–petroleum ether) to yield 3 (0.98 g, 73%). Rf = 0.29
(20 : 1 DCM–MeOH). [α]D = +85.7 (c = 1.0 in DCM).
1H NMR
(500 MHz, CDCl3): δ = 5.45 (bs, 7 H, NHBoc), 5.28 (t, 7 H, J2,3 =
J3,4 = 8.9 Hz, H-3), 5.12 (d, 7 H, J1,2 = 3.9 Hz, H-1), 4.84 (dd,
7 H, H-2), 4.20 (m, 7 H, H-5), 3.80 (t, 7 H, J4,5 = 8.6 Hz, H-4),
3.35 (bq, 14 H, 3JH,H = 6.5 Hz, CH2NHBoc), 3.17 (dd, 7 H, J5,6a =
2.1 Hz, J6a,6b = 11.7 Hz, H-6a), 3.07 (dd, 7 H, J5,6b = 5.9 Hz,
H-6b), 2.79, 2.77 (2 dt, 14 H, 2JH,H = 13.4 Hz,
3JH,H = 6.7 Hz,
CH2SCyst), 2.47–2.20 (m, 28 H, CH2CO), 1.47 (s, 63 H, CMe3),
1.12 (2 t, 42 H, 3JH,H = 7.5 Hz, CH3);
13C NMR (125.7 MHz,
CDCl3): δ = 174.1, 172.6 (2 CO ester), 156.0 (CO carbamate),
96.8 (C-1), 79.4 (CMe3), 79.0 (C-4), 71.3 (C-5), 70.7 (C-3), 70.2
(C-2), 40.4 (CH2NHBoc), 33.8 (CH2SCyst, C-6), 28.5 (CMe3), 27.3,
27.2 (CH2CO), 8.9 (CH3). ESI-MS: m/z 1540.3 [M + 2 Na]
2+,
3057.0 [M + Na]+. Elemental analysis calculated (%) for
C133H217N7O56S7: C 52.64, H 7.21, N 3.23, S 7.40; found:
C 52.64, H 7.27, N 3.20, S 7.69.
Heptakis[2,3-di-O-butanoyl-6-(2-tert-butoxycarbonylamino-
ethylthio)]cyclomaltoheptaose (4). To a solution of 1 33 (1.21 g,
0.54 mmol) in dry DMF (40 mL) under nitrogen atmosphere,
DMAP (2.77 g, 22.7 mmol, 3 eq.) and butanoic anhydride
(4.9 mL, 30.2 mmol, 4 eq.) were added at 0 °C. The reaction
mixture was allowed to warm to rt and stirred overnight. Then,
MeOH (150 mL) was added and the reaction mixture was
further stirred for 1 h. The solvents were removed under
reduced pressure and H2O (70 mL) was added to the reaction
mixture, which was then extracted with DCM (4 × 70 mL). The
organic layer was successively washed with 1 N aq. HCl (2 ×
60 mL) and a saturated aqueous solution of NaHCO3 (60 mL),
dried over Na2SO4, filtered and reduced under vacuum. The
crude product was purified by flash column chromatography
(1 : 3 → 1 : 1 EtOAc–petroleum ether) to yield 4 as a white
powder (1.36 g, 78%). Rf = 0.31 (20 : 1 DCM–MeOH). [α]D =
+101.6 (c = 1.0 in DCM). 1H NMR (500 MHz, CDCl3): δ = 5.47
(bs, 7 H, NHBoc), 5.29 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.14 (d,
7 H, J1,2 = 3.9 Hz, H-1), 4.82 (dd, 7 H, H-2), 4.19 (m, 7 H, H-5),
3.81 (t, 7 H, J4,5 = 8.6 Hz, H-4), 3.34 (bq, 14 H,
3JH,H = 6.5 Hz,
CH2NHBoc), 3.16 (dd, 7 H, J5,6a = 2.1 Hz, J6a,6b = 11.8 Hz,
H-6a), 3.07 (dd, 7 H, J5,6b = 5.8 Hz, H-6b), 2.79, 2.77 (2 dt,
14 H, 2JH,H = 13.1 Hz,
3JH,H = 6.6 Hz, CH2SCyst), 2.42–2.14 (m,
28 H, CH2CO), 1.63 (m, 28 H, CH2CH3), 1.47 (s, 63 H, CMe3),
0.98, 0.94 (2 t, 42 H, 3JH,H = 7.5 Hz, CH3);
13C NMR
(125.7 MHz, CDCl3): δ = 173.2, 171.6 (2 CO ester), 156.0
(CO carbamate), 96.5 (C-1), 79.3 (CMe3), 78.8 (C-4), 71.3 (C-5),
70.4 (C-3), 70.1 (C-2), 40.4 (CH2NHBoc), 35.9, 35.7 (CH2CO),
33.8 (CH2SCyst, C-6), 28.5 (CMe3), 18.1 (CH2CH3), 13.6, 13.5
(CH3). ESI-MS: m/z 1638.4 [M + 2 Na]
2+, 3253.4 [M + Na]+.
Elemental analysis calculated (%) for C147H245N7O56S7: C 54.65,
H 7.64, N 3.03, S 6.95; found: C 54.81, H 7.34, N 2.87, S 6.97.
Heptakis[6-(2-aminoethylthio)-2,3-di-O-propanoyl]cyclo-
maltoheptaose (8). Treatment of heptacarbamate 3 (0.31 g,
0.10 mmol) with a 1 : 1 TFA–DCM mixture at rt for 2 h, fol-
lowed by repeated co-evaporation with water and freeze-drying
from a 0.1 N aq. HCl solution, gave pure compound 8 as its
heptahydrochloride salt in quantitative yield (262 mg). [α]D =
+59.2 (c = 1.0 in MeOH). 1H NMR (500 MHz, MeOD): δ = 5.42
(t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 5.26 (d, 7 H, J1,2 = 3.6 Hz, H-1),
4.85 (dd, 7 H, H-2), 4.15 (m, 7 H, H-5), 3.99 (t, 7 H, J4,5 =
9.0 Hz, H-4), 3.30 (t, 14 H, 3JH,H = 7.0 Hz, CH2NH2), 3.19–3.12
(m, 21 H, H-6a, CH2SCyst), 3.07 (m, 7 H, H-6b), 2.51–2.30 (m,
28 H, CH2CO), 1.15 (2 t, 42 H,
3JH,H = 7.5 Hz, CH3);
13C NMR
(125.7 MHz, MeOD): δ = 173.9, (2 CO ester), 96.4 (C-1), 78.2
(C-4), 72.4 (C-5), 70.5 (C-3), 70.4 (C-2), 38.9 (CH2NH2), 33.2
(C-6), 30.3 (CH2SCyst), 27.1, 26.9 (CH2CO), 7.9 (CH3). ESI-MS:
m/z 1167.4 [M + 2 H]2+, 2333.9 [M + H]+. Elemental analysis
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calculated (%) for C98H168Cl7N7O42S7·7H2O: C 43.35, H 6.76,
N 3.61, S 8.27; found: C 43.42, H 6.53, N 3.72, S 7.90.
Heptakis[6-(2-aminoethylthio)-2,3-di-O-butanoyl]cyclomalto-
heptaose (9). Treatment of heptacarbamate 4 (0.30 g, 93 µmol)
with TFA following the procedure described for the synthesis
of compound 8, followed by freeze-drying from a 0.1 N aq. HCl
solution, gave pure compound 9 as its heptahydrochloride salt
in quantitative yield (0.26 g). [α]D = +65.0 (c = 1.0 in MeOH).
1H
NMR (500 MHz, MeOD, 313 K): δ = 5.40 (t, 7 H, J2,3 = J3,4 = 9.3
Hz, H-3), 5.22 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.83 (dd, 7 H, H-2),
4.14 (m, 7 H, H-5), 3.94 (t, 7 H, J4,5 = 8.7 Hz, H-4), 3.32–3.26
(m, 21 H, CH2NH2, H-6a), 3.13–2.98 (m, 21 H, H6-b, CH2SCyst),
2.49–2.25 (m, 28 H, CH2CO), 1.67 (m, 28 H, CH2CH3), 0.98,
0.99 (2 t, 42 H, 3JH,H = 7.4 Hz, CH3);
13C NMR (125.7 MHz,
MeOD, 313 K): δ = 173.0, 172.8 (2 CO ester), 96.5 (C-1), 78.4
(C-4), 72.5 (C-5), 70.4 (C-3), 70.1 (C-2), 39.0 (CH2NH2), 35.7,
35.5 (CH2CO), 33.3 (C-6), 30.4 (CH2SCyst), 17.8 (CH2CH3), 12.6
(CH3). ESI-MS: m/z 1265.6 [M + 2 H]
2+, 2530.1 [M + H]+.
Elemental analysis calculated (%) for C112H196Cl7N7O42S7·7H2O:
C 46.20, H 7.27, N 3.37, S 7.71; found: C 45.89, H 6.91, N 3.19,
S 7.63.
Heptakis[6-(2-(N′-(2-tert-butoxycarbonylaminoethyl)thio-
ureido)ethylthio)-2,3-di-O-propanoyl]cyclomaltoheptaose (12).
To a solution of compound 8 (100 mg, 39 µmol) and Et3N
(94 µL, 0.68 mmol, 2.5 eq.) in DCM (2 mL) a solution of 2-(tert-
butoxycarbonylamino)ethyl isothiocyanate43 (66 mg,
0.32 mmol, 1.2 eq.) in DCM (1 mL) was added dropwise. The
reaction mixture was stirred overnight at rt. After evaporation
of the solvent under reduced pressure, the residue was purified
by flash column chromatography (40 : 1 → 15 : 1 DCM–MeOH)
to yield compound 12 as an oﬀ-white powder (108 mg, 75%).
Rf = 0.19 (20 : 1 DCM–MeOH). [α]D = +73.9 (c = 1.0 in DCM).
1H
NMR (500 MHz, CDCl3): δ = 7.25 (2 bs, 14 H, NHCS), 5.63 (bs,
7 H, NHBoc), 5.27 (t, 7 H, J2,3 = J3,4 = 8.5 Hz, H-3), 5.11 (d, 7 H,
J1,2 = 2.7 Hz, H-1), 4.82 (dd, 7 H, H-2), 4.20 (m, 7 H, H-5), 3.78
(t, 7 H, J4,5 = 8.2 Hz, H-4), 3.73, 3.61 (2 m, 28 H, CH2NHCS),
3.30 (bs, 14 H, CH2NHBoc), 3.22 (bd, 7 H, J6a,6b = 13.1 Hz,
H-6a), 3.04 (m, 7 H, H-6b), 2.95, 2.83 (2 m, 14 H, CH2SCyst),
2.42–2.17 (m, 28 H, CH2CO), 1.45 (s, 63 H, CMe3), 1.12, 1.10
(2 t, 42 H, 3JH,H = 7.5 Hz, CH3);
13C NMR (125.7 MHz, CDCl3,
313 K): δ = 182.3 (CS), 174.1, 173.1 (2 CO ester), 157.3 (CO car-
bamate), 96.7 (C-1), 79.0 (CMe3), 78.3 (C-4), 71.8 (C-5), 70.8
(C-3), 70.4 (C-2), 43.8 (CH2NHCS), 39.6 (CH2NHBoc), 33.7
(C-6), 32.7 (CH2SCyst), 27.6 (CMe3), 27.1, 27.0 (CH2CO), 8.0
(CH3). ESI-MS: m/z 1286.3 [M + 2 Na + K]
3+, 1897.8 [M +
2 Na]2+, 1917.5 [M + Na + K]2+. Elemental analysis calculated
(%) for C154H259N21O56S14: C 49.33, H 6.96, N 7.84, S 11.97;
found: C 49.25, H 7.17, N 7.55, S 11.93.
Heptakis[2,3-di-O-butanoyl-6-(2-(N′-(2-tert-butoxycarbonyl-
aminoethyl)thioureido)ethylthio)]cyclomaltoheptaose (13). To a
solution of compound 9 (81 mg, 29 µmol) and Et3N (71 µL,
0.51 mmol, 2.5 eq.) in DCM (2 mL) a solution of 2-(tert-butoxy-
carbonylamino)ethyl isothiocyanate43 (49 mg, 0.24 mmol, 1.2
eq.) in DCM (1 mL) was added dropwise. The reaction mixture
was stirred overnight at rt. Then, the solvent was evaporated
under reduced pressure and the resulting residue was purified
by flash column chromatography (40 : 1 → 15 : 1 DCM–MeOH)
to yield compound 13 as an oﬀ-white powder (97 mg, 84%).
Rf = 0.20 (20 : 1 DCM–MeOH). [α]D = +38.5 (c = 1.0 in DCM).
1H NMR (500 MHz, MeOD, 313 K): δ = 5.36 (t, 7 H, J2,3 = J3,4 =
8.2 Hz, H-3), 5.19 (d, 7 H, J1,2 = 2.7 Hz, H-1), 4.83 (dd, 7 H,
H-2), 4.23 (m, 7 H, H-5), 3.96 (t, 7 H, J4,5 = 8.0 Hz, H-4), 3.77,
3.60 (2 m, 28 H, CH2NHCS), 3.28 (m, 21 H, CH2NHBoc, H-6a),
3.20 (dd, 7 H, J5,6a = 4.1 Hz, J6a,6b = 9.8 Hz, H-6b), 2.97, 2.93
(2 m, 14 H, CH2SCyst), 2.46–2.23 (m, 28 H, CH2CO), 1.67 (m,
28 H, CH2CH3), 1.47 (s, 63 H, CMe3), 1.00, 0.97 (2 t, 42 H,
3JH,H = 7.2 Hz, CH3).
13C NMR (125.7 MHz, 313 K, MeOD): δ =
182.2 (CS), 173.1, 172.0 (2 CO ester), 157.3 (CO carbamate),
96.5 (C-1), 79.0 (CMe3), 78.2 (C-4), 71.9 (C-5), 70.5 (C-3), 70.3
(C-2), 43.9 (CH2NHCS), 39.6 (CH2NHBoc), 35.7, 35.6 (CH2CO),
33.7 (C-6), 32.7 (CH2SCyst), 27.6 (CMe3), 17.9, 17.8 (CH2CH3),
12.7 (CH3). ESI-MS: m/z 1995.6 [M + 2 Na]
2+, 3966.6 [M + Na]+.
Elemental analysis calculated (%) for C168H287N21O56S14:
C 51.13, H 7.33, N 7.45, S 11.38; found: C 51.34, H 7.36,
N 7.48, S 11.29.
Heptakis[6-(2-(N′-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)
ethyl)amino)ethyl)thioureido)ethylthio)-2,3-di-O-propanoyl]
cyclomaltoheptaose (16). To a solution of compound 8
(95 mg, 37 µmol) and Et3N (90 µL, 0.64 mmol, 2.5 eq.) in DCM
(2 mL) a solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)
amino]ethyl isothiocyanate33 (120 mg, 0.31 mmol, 1.2 eq.) in
DCM (1 mL) was added dropwise. The reaction mixture was
stirred overnight at rt. After evaporation of the solvent under
reduced pressure, the residue was purified by flash column
chromatography (40 : 1 → 15 : 1 DCM–MeOH) to yield com-
pound 16 as an oﬀ-white powder (114 mg, 62%). Rf = 0.64 (9 : 1
DCM–MeOH). [α]D = +37.8 (c = 1.0 in MeOH).
1H NMR
(500 MHz, MeOD, 323 K): δ = 5.36 (t, 7 H, J2,3 = J3,4 = 8.7 Hz,
H-3), 5.18 (d, 7 H, J1,2 = 3.3 Hz, H-1), 4.83 (dd, 7 H, H-2), 4.25
(m, 7 H, H-5), 3.97 (t, 7 H, J4,5 = 8.3 Hz, H-4), 3.81 (bt, 14 H,
CH2CH2SCyst), 3.56 (bt, 14 H, NCH2CH2NHCS), 3.23 (m, 42 H,
H-6a, H-6b, CH2NHBoc), 2.96 (m, 14 H, CH2SCyst), 2.74 (t, 14 H,
3JH,H = 6.0 Hz, NCH2CH2NHCS), 2.64 (t, 28 H,
3JH,H = 6.0 Hz,
CH2CH2NHBoc), 2.50–2.27 (m, 28 H, CH2CO), 1.48 (s, 126 H,
CMe3), 1.15, 1.13 (2 t, 42 H,
3JH,H = 7.7 Hz, CH3);
13C NMR
(125.7 MHz, MeOD, 313 K): δ = 182.3 (CS), 174.0, 173.1 (2 CO
ester), 157.1 (CO carbamate), 96.7 (C-1), 78.9 (CMe3), 78.4
(C-4), 71.8 (C-5), 70.8 (C-3), 70.4 (C-2), 54.3 (CH2CH2NHBoc),
53.3 (NCH2CH2NHCS), 44.0 (CH2CH2SCyst), 42.0
(NCH2CH2NHCS), 38.6 (CH2NHBoc), 33.8 (C-6), 33.0
(CH2SCyst), 27.7 (CMe3), 27.1, 27.0 (CH2CO), 8.1, 8.0 (CH3).
ESI-MS: m/z 1723.8 [M + 3 K]3+, 2550.2 [M + 2 Na]2+, 2558.3
[M + Na + K]2+, 2543.4 [M + Cl − H]2−. Elemental analysis
calculated (%) for C217H385N35O70S14: C 51.57, H 7.68, N 9.70,
S 8.88; found: C 51.18, H 7.67, N 9.23, S 8.99.
Heptakis[2,3-di-O-butanoyl-6-(2-(N′-(2-(N,N-di-(2-(N-tert-butoxy-
carbonylamino)ethyl)amino)ethyl)thioureido)ethylthio)]cyclo-
maltoheptaose (17). To a solution of compound 9 (100 mg,
36 µmol) and Et3N (87 µL, 0.63 mmol, 2.5 eq.) in DCM (2 mL)
a solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]
ethyl isothiocyanate33 (117 mg, 0.30 mmol, 1.2 eq.) in DCM
(1 mL) was added dropwise. The reaction mixture was stirred
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overnight at rt. Then, the solvent was evaporated under
reduced pressure and the resulting residue was purified by
flash column chromatography (40 : 1 → 15 : 1 DCM–MeOH) to
give compound 17 (139 mg, 74%). Rf = 0.63 (20 : 1 DCM–
MeOH). [α]D = +38.1 (c = 0.99 in MeOH).
1H NMR (500 MHz,
MeOD, 323 K): δ = 5.36 (t, 7 H, J2,3 = J3,4 = 8.7 Hz, H-3), 5.17 (d,
7 H, J1,2 = 3.7 Hz, H-1), 4.83 (dd, 7 H, H-2), 4.23 (m, 7 H, H-5),
3.97 (t, 7 H, J4,5 = 8.3 Hz, H-4), 3.81 (t, 14 H,
3JH,H = 6.5 Hz,
CH2CH2NCyst), 3.56 (m, 14 H, NCH2CH2NHCS), 3.29 (m, 7 H,
H-6a), 3.21 (dd, 7 H, J5,6b = 5.0 Hz, J6a,6b = 14.3 Hz, H-6b), 3.16
(t, 28 H, 3JH,H = 6.5 Hz, CH2NHBoc), 2.96 (m, 14 H, CH2SCyst),
2.74 (t, 14 H, 3JH,H = 6.5 Hz, NCH2CH2NHCS), 2.53 (t, 28 H,
3JH,
H = 6.5 Hz, CH2CH2NHBoc), 2.47–2.23 (m, 28 H, CH2CO), 1.67
(m, 28 H, CH2CH3), 1.48 (s, 126 H, CMe3), 1.01, 0.98 (2 t, 42 H,
3JH,H = 7.5 Hz, CH3).
13C NMR (125.7 MHz, MeOD, 313 K): δ =
173.1, 172.1 (2 CO ester), 157.1 (CO carbamate), 96.6 (C-1),
79.1 (CMe3), 78.3 (C-4), 72.0 (C-5), 70.7 (C-3), 70.3 (C-2), 54.3
(CH2CH2NHBoc), 53.5 (NCH2CH2NHCS), 44.1 (CH2CH2SCyst),
41.9 (NCH2CH2NHCS), 38.4 (CH2NHBoc), 35.8, 35.6 (CH2CO),
34.0 (C-6), 33.0 (CH2SCyst), 27.7 (CMe3), 17.9, 17.8 (CH2CH3),
12.7 (CH3). ESI-MS: m/z 1772.9 [M + 3 Na]
3+, 2647.9
[M + 2 Na]2+. Elemental analysis calculated (%) for
C231H413N35O70S14: C 52.85, H 7.93, N 9.34, S 8.55; found: C
52.77, H 7.95, N 9.36, S 8.38.
Heptakis[2,3-di-O-acetyl-6-(2-(N′-(2-aminoethyl)thioureido)
ethylthio)]cyclomaltoheptaose heptahydrochloride (7Ac).
Treatment of compound 11 44 (50 mg, 14 µmol) with an-
hydrous TFA (100 µL) at rt for 5 min, followed by freeze-drying
immediately from a 0.1 N aq. HCl solution, aﬀorded pure
paCD 7Ac in virtually quantitative yield (43 mg). [α]D = +35.2
(c = 0.5 in MeOH). 1H NMR (500 MHz, DMSO-d6, 333 K): δ =
8.12 (bs, 14 H, NH2), 7.97, 7.75 (2 bs, 14 H, NHCS), 5.22 (t,
7 H, J2,3 = J3,4 = 9.0 Hz, H-3), 5.11 (d, 7 H, J1,2 = 3.7 Hz, H-1),
4.73 (dd, 7 H, H-2), 4.14 (m, 7 H, H-5), 3.90 (t, 7 H, J4,5 =
8.8 Hz, H-4), 3.72, 3.63 (2 bq, 28 H, CH2NHCS), 3.12 (m, 14 H,
H-6a, H-6b), 3.02 (bt, 14 H, CH2NH2), 2.82 (m, 14 H, CH2SCyst),
2.02, 2.00 (2s, 42 H, COCH3);
13C NMR (100.6 MHz, DMSO-d6,
323 K): δ = 183.2 (CS), 170.5, 169.7 (2 CO ester), 97.0 (C-1), 78.8
(C-4), 71.6 (C-5), 70.8 (C-2, C-3), 44.0, 41.7 (CH2NHCS), 38.8
(CH2NH2), 33.7 (C-6), 32.8 (CH2SCyst), 21.0 (COCH3). ESI-MS:
m/z 713.8 [M + 4 H]4+, 951.7 [M + 3 H]3+, 1426.7 [M + 2 H]2+.
Elemental analysis calculated (%) for C105H182Cl7N21O42S14:
C 40.58, H 5.90, N 9.46, S 14.44; found: C 40.54, H 6.15,
N 9.33, S 14.79.
Heptakis[6-(2-(N′-(2-aminoethyl)thioureido)ethylthio)-2,3-di-
O-propanoyl]cyclomaltoheptaose heptahydrochloride (7Pr).
Treatment of heptacarbamate 12 (35 mg, 9.3 µmol) with an-
hydrous TFA (90 µL) at rt for 5 min, followed by freeze-drying
immediately from a 0.1 N aq. HCl solution, yielded pure paCD
7Pr (28 mg, 90%). [α]D = +36.9 (c = 0.5 in MeOH).
1H NMR
(500 MHz, DMSO-d6, 333 K): δ = 8.11 (bs, 14 H, NH2), 7.96,
7.75 (2 bs, 14 H, NHCS), 5.24 (t, 7 H, J2,3 = J3,4 = 8.9 Hz, H-3),
5.10 (d, 7 H, J1,2 = 3.4 Hz, H-1), 4.74 (dd, 7 H, H-2), 4.16 (m,
7 H, H-5), 3.91 (t, 7 H, J4,5 = 8.6 Hz, H-4), 3.71, 3.64 (2 bq,
28 H, CH2NHCS), 3.12 (m, 14 H, H-6a, H-6b), 3.02 (bt, 14 H,
CH2NH2), 2.83 (m, 14 H, CH2SCyst), 2.37–2.20 (m, 28 H,
CH2CO), 1.04, 1.03 (2 t, 42 H,
3JH,H = 7.5 Hz, CH3);
13C NMR
(125.7 MHz, DMSO-d6, 323 K): δ = 183.2 (CS), 173.7, 172.9
(2 CO ester), 96.9 (C-1), 78.7 (C-4), 71.7 (C-5), 70.9 (C-3), 70.6
(C-2), 43.1, 41.7 (CH2NHCS), 38.9 (CH2NH2), 33.8 (C-6), 32.8
(CH2SCyst), 27.2 (CH2CO), 9.1 (CH3). ESI-MS: m/z 762.7 [M +
4 H]4+, 1017.6 [M + 3 H]3+, 1525.5 [M + 2 H]2+, 3048.8 [M + H]+.
Elemental analysis calculated (%) for C119H210Cl7N21O42S14:
C 43.26, H 6.41, N 8.90, S 13.59; found: C 43.34, H 6.33,
N 8.84, S 13.34.
Heptakis[6-(2-(N′-(2-aminoethyl)thioureido)ethylthio)-2,3-di-
O-butanoyl]cyclomaltoheptaose heptahydrochloride (7But).
Treatment of heptacarbamate 13 (88 mg, 22 µmol) with an-
hydrous TFA (0.5 mL) at rt for 5 min, followed by freeze-drying
immediately from a 0.1 N aq. HCl solution, yielded pure paCD
7But in quantitative yield (78 mg). [α]D = +34.3 (c = 0.5 in
MeOH). 1H NMR (500 MHz, DMSO-d6, 333 K): δ = 8.15 (bs,
14 H, NH2), 7.97, 7.75 (2 bs, 14 H, NHCS), 5.26 (t, 7 H, J2,3 =
J3,4 = 8.8 Hz, H-3), 5.11 (d, 7 H, J1,2 = 3.0 Hz, H-1), 4.73 (dd,
7 H, H-2), 4.17 (m, 7 H, H-5), 3.91 (t, 7 H, J4,5 = 8.9 Hz, H-4),
3.73, 3.65 (2 bq, 28 H, CH2NHCS), 3.11 (m, 14 H, H-6a, H-6b),
3.03 (bt, 14 H, CH2NH2), 2.84 (m, 14 H, CH2SCyst), 2.34, 2.22
(2 m, 28 H, CH2CO), 1.57 (m, 28 H, CH2CH3), 0.92, 0.89 (2 t, 42
H, 3JH,H = 7.4 Hz, CH3);
13C NMR (125.7 MHz, DMSO-d6,
333 K): δ = 183.4 (CS), 172.8, 171.8 (2 CO ester), 96.7 (C-1), 78.6
(C-4), 71.6 (C-5), 70.7, 70.5 (C-3, C-2), 44.2, 43.1 (CH2NHCS),
39.0 (CH2NH2), 35.8, 35.7 (CH2CO), 34.1 (C-6), 32.9 (CH2SCyst),
18.1, 18.0 (CH2CH3), 13.7 (CH3). ESI-MS: m/z 812.5 [M + 4 H]
4+,
1082.4 [M + 3 H]3+, 1623.1 [M + 2 H]2+, 3245.1 [M + H]+.
Elemental analysis calculated (%) for C133H238Cl7N21O42S14:
C 45.63, H 6.85, N 8.40, S 12.82; found: C 45.51, H 7.01,
N 8.35, S 12.57.
Heptakis[2,3-di-O-acetyl-6-(2-(N′-(2-(N,N-di-(2-aminoethyl)
amino)ethyl)thioureido)ethylthio)]cyclomaltoheptaose tetra-
decahydrochloride (21Ac). Treatment of compound 15 (50 mg,
10 µmol) with anhydrous TFA (100 µL) at rt for 5 min, followed
by freeze-drying immediately from a 0.1 N aq. HCl solution,
aﬀorded pure paCD 21Ac in quantitative yield (41 mg). [α]D =
+25.1 (c = 0.5 in MeOH). 1H NMR (500 MHz, 10 : 1 MeOD-D2O,
333 K): δ = 5.33 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.21 (d, 7 H,
J1,2 = 3.6 Hz, H-1), 4.83 (dd, 7 H, H-2), 4.20 (m, 7 H, H-5), 3.96
(t, 7 H, J4,5 = 8.6 Hz, H-4), 3.88 (bt, 14 H, CH2CH2SCyst), 3.78
(bt, 14 H, NCH2CH2NHCS), 3.39 (m, 28 H, CH2NH2), 3.33–3.18
(m, 56 H, H-6a, H-6b, CH2CH2NH2, NCH2CH2NHCS), 2.95 (m,
14 H, CH2SCyst), 2.10, 2.08 (2s, 42 H, COCH3);
13C NMR
(100.6 MHz, 15 : 1 MeOD-D2O, 323 K): δ = 182.9 (CS), 171.3,
170.6 (2 CO ester), 96.7 (C-1), 78.7 (C-4), 72.1 (C-5), 70.9 (C-3,
C-2), 52.7 (NCH2CH2NHCS), 51.1 (CH2CH2NH2), 44.1
(CH2CH2SCyst), 40.4 (NCH2CH2NHCS), 36.4 (CH2NH2), 33.7
(C-6), 32.7 (CH2SCyst), 19.9, 19.8 (COCH3). ESI-MS: m/z 691.7
[M + 5 H]5+, 864.6 [M + 4 H]4+, 1152.7 [M + 3 H]3+, 1728.7 [M +
2 H]2+. Elemental analysis calculated (%) for
C133H259Cl14N35O42S14: C 40.28, H 6.58, N 12.36, S 11.32;
found: C 40.10, H 6.66, N 12.56, S 11.32.
Heptakis[6-(2-(N′-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thiour-
eido)ethylthio)-2,3-di-O-propanoyl]cyclomaltoheptaose tetradeca-
hydrochloride (21Pr). Treatment of compound 16 (100 mg,
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19.8 µmol) with anhydrous TFA (0.5 mL) at rt for 5 min, fol-
lowed by freeze-drying immediately from a 0.1 N aq. HCl solu-
tion, aﬀorded pure paCD 21Pr in quantitative yield (82 mg).
[α]D = +33.2 (c = 0.25 in MeOH).
1H NMR (500 MHz, 10 : 1
MeOD–D2O, 323 K): δ = 5.32 (t, 7 H, J2,3 = J3,4 = 8.6 Hz, H-3),
5.18 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.84 (dd, 7 H, H-2), 4.21 (m,
7 H, H-5), 3.96 (t, 7 H, J4,5 = 8.3 Hz, H-4), 3.77 (bt, 14 H,
CH2CH2SCyst), 3.72 (bt, 14 H, NCH2CH2NHCS), 3.23 (m, 42 H,
H-6a, H-6b, CH2NH2), 3.00 (t, 28 H,
3JH,H = 5.9 Hz,
CH2CH2NH2), 2.94 (m, 14 H, CH2SCyst), 2.89 (t, 14 H,
3JH,H =
5.9 Hz, NCH2CH2NHCS), 2.49–2.27 (m, 28 H, CH2CO), 1.13,
1.11 (2 t, 42 H, 3JH,H = 7.5 Hz, CH3);
13C NMR (125.7 MHz, 5 : 1
MeOD–D2O, 323 K): δ = 182.2 (CS), 174.9, 173.7 (2 CO ester),
96.6 (C-1), 78.3 (C-4), 72.0 (C-5), 70.9 (C-3), 70.4 (C-2), 52.2
(NCH2CH2NHCS), 51.0 (CH2CH2NH2), 44.1 (CH2CH2SCyst), 40.8
(NCH2CH2NHCS), 36.8 (CH2NH2), 33.9 (C-6), 32.7 (CH2SCyst),
27.2 (CH2CO), 8.2, 8.1 (CH3). ESI-MS: m/z 931.1 [M + H +
3 Na]4+, 1239.9 [M + 3 Na]3+, 1827.3 [M + 2 H]2+. Elemental
analysis calculated (%) for C147H287Cl14N35O42S14·7H2O:
C 41.17, H 7.07, N 11.43, S 10.47; found: C 40.93, H 6.89,
N 11.35, S 10.22.
Heptakis[6-(2-(N′-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thio-
ureido)ethylthio)-2,3-di-O-butanoyl]cyclomaltoheptaose tetra-
decahydrochloride (21But). Treatment of compound 17 (63 mg,
12 µmol) with anhydrous TFA (200 µL) at rt for 5 min, followed
by freeze-drying immediately from a 0.1 N aq. HCl solution,
aﬀorded pure paCD 21But in virtually quantitative yield
(51 mg). [α]D = +30.0 (c = 0.5 in MeOH).
1H NMR (500 MHz,
10 : 1 MeOD–D2O, 333 K): δ = 5.33 (t, 7 H, J2,3 = J3,4 = 8.6 Hz,
H-3), 5.20 (d, 7 H, J1,2 = 3.6 Hz, H-1), 4.86 (dd, 7 H, H-2), 4.20
(m, 7 H, H-5), 3.97 (t, 7 H, J4,5 = 8.4 Hz, H-4), 3.84 (bt, 14 H,
CH2CH2SCyst), 3.80 (bq, 14 H, NCH2CH2NHCS), 3.35 (t, 28 H,
3JH,H = 6.2 Hz, CH2NH2), 3.29 (m, 14 H, H-6a, H-6b), 3.24 (t,
28 H, 3JH,H = 7.4 Hz, CH2CH2NH2), 3.11 (t, 14 H,
3JH,H = 6.4 Hz,
NCH2CH2NHCS), 2.96 (m, 14 H, CH2SCyst), 2.46–2.24 (m, 28 H,
CH2CO), 1.66 (m, 28 H, CH2CH3), 1.00, 0.96 (2 t, 42 H,
3JH,H =
7.5 Hz, CH3);
13C NMR (100.6 MHz, 10 : 1 MeOD–D2O, 323 K):
δ = 173.6, 172.3 (2 CO ester), 96.5 (C-1), 78.2 (C-4), 72.0 (C-5),
70.6 (C-3), 70.3 (C-2), 52.4 (NCH2CH2NHCS), 51.2
(CH2CH2NH2), 44.1 (CH2CH2SCyst), 40.9 (NCH2CH2NHCS), 36.9
(CH2NH2), 35.7, 35.6 (CH2CO), 33.9 (C-6), 32.7 (CH2SCyst), 18.0,
17.9 (CH2CH3), 12.7 (CH3). ESI-MS: m/z 978.3 [M + H + 3 Na]
4+,
1283.2 [M + 3 H]3+. Elemental analysis calculated (%) for
C161H315Cl14N35O42S14: C 44.36, H 7.28, N 11.25, S 10.30;
found: C 44.54, H 7.44, N 11.36, S 10.55.
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